XML 42 R15.htm IDEA: XBRL DOCUMENT
v3.22.4

Fair Value Measurements | 12 Months Ended
--- | ---
Dec. 31, 2022
Fair Value Disclosures [Abstract] |
FAIR VALUE MEASUREMENTS | 4. Fair Value Measurements The following table presents the Company’s financial assets and liabilities that are measured at fair value (in thousands):
|  | Fair value measurements at December 31, 2022 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 2,184 |  |  | $ | 2,184 |  |  | $ | — |  |  | $ | — |
Total assets measured at fair value |  | $ | 2,184 |  |  | $ | 2,184 |  |  | $ | — |  |  | $ | — |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities |  | $ | 1,231 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,231 |
Other long-term liabilities |  |  | 163 |  |  |  | — |  |  |  | — |  |  |  | 163 |
Total liabilities measured at fair value |  | $ | 1,394 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,394 |
|  | Fair value measurements at December 31, 2021 |
|  | Balance |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 4,338 |  |  | $ | 4,338 |  |  | $ | — |  |  | $ | — |
Total assets measured at fair value |  | $ | 4,338 |  |  | $ | 4,338 |  |  | $ | — |  |  | $ | — |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities |  | $ | 35,700 |  |  | $ | — |  |  | $ | — |  |  | $ | 35,700 |
Total liabilities measured at fair value |  | $ | 35,700 |  |  | $ | — |  |  | $ | — |  |  | $ | 35,700 |
Cash and cash equivalents The Company’s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. Derivative liabilities The Company recorded a gain of $8.3 million, loss of $0.3 million, and gain of $0.8 million on derivative liabilities for the years ended December 31, 2022, 2021, and 2020, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note 7) and Private Warrants. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $30.4 million immediately after entry into Amendment No. 4 (see Note 7) associated with the Scilex Pharma Notes on June 2, 2022. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No. 4. Significant Level 3 assumptions used in the measurement included a 6.1% risk adjusted net sales forecast and an effective debt yield of 21.5%. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 7) and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December 31, 2022. At the closing of the Business Combination, the Company assumed a derivative warrant liability of $2.5 million related to Private Warrants (See Note 8). The fair value of derivative warrant liability related to Private Warrants was $1.2 million as of December 31, 2022. The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2022:
|  | Fair value |
Ending Balance at December 31, 2019 |  | $ | 33,400 |
Loan derivative liability |  |  | 2,800 |
Re-measurement of fair value |  |  | (800 | )
Ending Balance at December 31, 2020 |  | $ | 35,400 |
Re-measurement of fair value |  |  | 300 |
Balance at December 31, 2021 |  | $ | 35,700 |
Private Warrant liability acquired as part of the Business Combination |  |  | 2,545 |
Forfeiture of Private Warrants |  |  | 1,696 |
Change in fair value measurement |  |  | (38,710 | )
Balance at December 31, 2022 |  | $ | 1,231 |
Warrant Liability Measurement The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. A summary of the inputs used in valuing the derivative warrant liabilities is as follows:
|  | December 31, 2022 |  |  | November 10, 2022 |
|  | Fair value |  |  | Fair Value |
Equity Value |  | $ | 3.99 |  |  | $ | 9.01 |
Exercise Price |  | $ | 11.50 |  |  | $ | 11.50 |
Term (in years) |  |  | 4.86 |  |  |  | 5.00 |
Volatility |  |  | 35.0 | % |  |  | 10.0 | %
Risk-free rate |  |  | 3.94 | % |  |  | 3.91 | %
Dividend yield |  |  | 0.00 | % |  |  | 0.00 | %
Call option value |  | $ | 0.30 |  |  | $ | 0.62 |
Contingent Consideration The Development Milestone Payment represents a liability under the scope of ASC Topic 480, Distinguishing Liabilities from Equity, as it pertains to a potential contractual obligation to settle a fixed value in a variable number of shares of Common Stock. Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $3.0 million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant Level 3 assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of 10.0%. As of December 31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $0.2 million. There were no transfers between fair value measurement levels during the years ended December 31, 2022, 2021, and 2020.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration